LDS/Medical Tests/Apolipoprotein A-II (APOA2) Gene Analysis

Apolipoprotein A-II (APOA2) Gene Analysis

APOA2 gene encodes apolipoprotein (apo-) A-II which is primarily expressed in liver. It is the most hydrophobic apolipoprotein and wild type apoA-II strongly binds to high density lipoprotein (HDL) in circulation. Due to its chemical characteristics, unbound apoA-II is prone to misfold and form amyloid although mutations in the APOA2 gene are a relatively rare cause of hereditary amyloidosis. Patients with this disorder typically demonstrate slowly progressive renal disease without significant involvement of other organs. Five mutations have been reported worldwide affecting 4 families. In all these cases, the mutation occurs in the stop codon resulting in a 21-residue extension on the C-terminal end of the protein. APOA2 gene analysis sequences the APOA2 gene to identify any alteration and assists in the confirmation of APOA2’s role in hereditary amyloidosis. Accurate diagnosis of APOA2-associated familial amyloidosis may require ruling out the effect of mutations in other genes, such as transthyretin, APOA1, lysozyme, gelsolin, cystatin C, and fibrinogen alpha chain.

  • Assist in the diagnosis and confirmation of APOA2-associated familial amyloidosis
  • Assist in the risk prediction of familial APOA2-associated familial amyloidosis
  • No reportable variation identified means a mutation was not detected. However, a negative result does not rule out the possibility that a genetic alteration is not identifiable by the methodology used or the possibility that rare polymorphisms leads to false-negative results
  • Detected variations are evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations, based on their known, predicted, or possible pathogenicity. In some cases, detected mutation could have undetermined significance or could be false-positive due to rare polymorphism

No reportable variants are identified (Negative for mutations analyzed)

DNA sequencing, conventional sequencing or Next generation sequencing (NGS).

Whole blood in lavender top or yellow top.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Analysis of other genes that may contribute to familial amyloidosis, including transthyretin, APOA1, lysozyme, gelsolin, cystatin C, and fibrinogen alpha chain.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login